CDT Equity Inc.
CDT
Positions held
Your positionsCDT isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $32,432 | Enterprise value | $460,173 | Trailing P/E | 0.00 | Forward P/E | — |
| PEG | — | Price / book | 0.00 | Beta | 1.56 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -69.7% | ROA | -23.4% | Debt / equity | 0.01 |
| Current ratio | 0.13 | Free cash flow | $19.62M | Analyst recommendation | none | Mean target | — |
| 52w high | $28,400.00 | 52w low | $0.80 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$4.6M | -$4.1M | -$21.3M | -$7.1M | -$6.0M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$3.0M | -$3.7M | -$21.2M | -$6.9M | -$5.0M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$39.2M | -$17.8M | -$0.5M | -$4.9M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$36.7M | -$15.1M | -$5.3M | -$3.2M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-29 · CDT Highlights Sarborg’s Expanding Quantum Computing IP Portfolio and Application to Drug Discovery
2026-09-25 · CDT Equity Inc. Announces Reverse Stock Split
2026-09-18 · CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo
2026-09-10 · CDT Highlights Sarborg’s Application of Signature Intelligence and Quantum Computing Models to Mental Health
2026-09-02 · CDT Provides Capital Update and Confirms No Nasdaq Deficiencies
2026-09-01 · CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth
2026-08-28 · CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio
2026-08-25 · CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market
2026-08-03 · CDT Equity to Boost Stake in Sarborg
2026-08-03 · CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion
2026-07-20 · CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane
2026-07-16 · CDT Equity Implements 1-for-10 Reverse Stock Split
Price (daily)
Full chart · RSI · MACD · patterns